-

Pfizer Declares Second-Quarter 2022 Dividend

Board of Directors approves quarterly cash dividend of $0.40 per share

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 second-quarter 2022 dividend on the company’s common stock, payable June 10, 2022, to holders of the Common Stock of record at the close of business on May 13, 2022. The second-quarter 2022 cash dividend will be the 334th consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Category: Finance

Contacts

Media Contact: PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226

Investor Contact: IR@Pfizer.com
+1 (212) 733-4848

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Media Contact: PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226

Investor Contact: IR@Pfizer.com
+1 (212) 733-4848

More News From Pfizer Inc.

Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC). At seven years, patients treated with LORBRENA had a 55% likelihood of re...

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

NEW YORK & SAN FRANCISCO & SUZHOU, China--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with nove...

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 2:00 p.m. EDT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning to...
Back to Newsroom